Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting

Onconova Therapeutics Inc ONTX has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's BMY Opdivo (nivolumab) in advanced KRAS mutated non-small cell lung cancer (NSCLC).
The trial included patients who failed two or more lines of prior therapy, and all have failed immune checkpoint inhibitors in various combinations.
Data showed that 2 of 7 (29%) evaluable patients achieved a partial response (PR), and 3 of 7 (43%) evaluable patients achieved disease control.
4 of 7 (57%) evaluable patients experienced progressive disease.
The combination of rigosertib and nivolumab has been well-tolerated, and the maximum tolerated dose has not been reached to date.
Treatment-related adverse events were primarily mild with two severe adverse events.
Three patients discontinued study drug (two moderate genitourinary toxicities, one dose-limiting severe hyponatremia)
No unexpected safety events or synergistic toxicities have been observed.
Onconova will host a webinar today at 4:30 p.m. ET to discuss the preliminary Phase 1/2a data.
Price Action: ONTX shares are up 25.5% at $6.15 during the market session on the last check Wednesday.